Leerink Partners analyst Stephanie Davis maintained a Buy rating on Inovalon (NASDAQ:INOV) on Wednesday, setting a price target of $45, which is approximately 21.79% above the present share price of $36.95.
Davis expects Inovalon to post earnings per share (EPS) of $0.06 for the third quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Inovalon, with an average price target of $39.33.
The analysts price targets range from a high of $45 to a low of $30.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $177.18 million and a net profit of $23.33 million. The company's market cap is $5.76 billion.
According to TipRanks.com, Leerink Partners analyst Stephanie Davis is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 18.8% and a 62.10% success rate.
Inovalon Holdings, Inc. engages in the development of cloud-based platforms for the healthcare industry. Its products include datasets, integration technologies, predictive analytics, and related services. The company was founded on September 11, 2014 and is headquartered in Bowie, MD.